Clinical Trials
31 trialsNCT04154956 2026-05-18
CARMEN-LC03
Sanofi
Phase 3 Terminated
NCT05407155 2026-04-23
BETTER
Fudan University
Phase NA Active not recruiting
NCT05889247 2026-01-09
PRELUCA
Zealand University Hospital
Phase NA Recruiting
NCT04504071 2025-09-08
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT04394624 2025-06-06
CARMEN-LC04
Sanofi
Phase 2 Terminated
NCT04836728 2025-03-13
CCICC-002b
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT04923945 2025-03-07
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
Hutchmed
Phase 3 Completed
NCT04994795 2024-11-21
DEEP-Lung-IV
Sophia Genetics SAS
Active not recruiting
NCT06517953 2024-07-25
IcomBine
Sun Yat-sen University
Phase 2 Recruiting
NCT06045767 2024-06-03
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
Tel Aviv Medical Center
Phase 2 Not yet recruiting
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT06083870 2023-12-20
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
Shanghai Chest Hospital
Phase 1 Recruiting
NCT06127940 2023-11-13
K-SAB
Karolinska University Hospital
Phase 1 Unknown
NCT04793815 2023-06-29
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Completed
NCT05800223 2023-04-05
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China
Phase 3 Recruiting
NCT01523340 2021-08-03
MENTOR
Chonnam National University Hospital
Completed
NCT04082182 2021-03-30
MIDRIX4-LUNG
University Hospital, Ghent
Phase 1 Unknown
NCT02443337 2020-12-09
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT02228421 2020-03-11
Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
PeriPharm
Terminated
NCT03656094 2019-12-09
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
Samsung Medical Center
Phase 2 Unknown
NCT03477474 2019-10-10
GEODE
Guardant Health, Inc.
Terminated
NCT01703091 2019-09-30
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01935154 2019-06-19
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Vaxon Biotech
Phase 2 Completed
NCT01848613 2018-11-09
VIVOS
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 4 Completed
NCT01752023 2018-10-17
NA_00067809
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01471964 2018-05-17
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT02299765 2017-11-27
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Sichuan University
Phase 4 Terminated
NCT01966003 2017-10-19
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Amgen
Phase 3 Completed
NCT02041468 2017-08-30
Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
Jewish General Hospital
Unknown
NCT03240549 2017-08-07
Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease
Beijing Hospital
Phase 2 Unknown
NCT00701558 2016-06-24
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Completed